netFormulary NHS
Pan Mersey
Area Prescribing Committee
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Section

Coronavirus guidance

Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.

The list of resources will be updated as new material becomes available so please check back regularly for updates.

The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice.

Malignant disease and immunosuppression

Review date: January 2022

Non-formulary drugs: Any drug or formulation not listed in the formulary is deemed to be non-formulary.

Off-label use: Drugs are included in the formulary for their licensed indications – where inclusion of off-label use is considered to be included in the formulary this is specifically stated in the formulary entry for the drug N.B. also see Paediatrics note below.

Paediatrics: Drugs are included in the formulary for paediatric use for their BNF for Children recommended indications (indicated by symbol View childrens BNF) which may be off-label, unless otherwise stated. All drugs are deemed to have the same RAG status as they have for adults unless stated otherwise.

NHS England Specialised Commissioning
Drugs carrying the NHS England logo are commissioned by them. Links to key documents, national programmes of care, and clinical reference groups are found below.

NHSE NHS England Specialised Commissioning: Key documents

NHSE NHS England Specialised Commissioning: National programmes of care and clinical reference groups

Medications which are indicated for medically assisted reproduction, including ovulation induction (e.g. clomifene, letrozole and tamoxifen) and assisted reproduction, such as In Vitro Fertilisation or Ex Vitro Fertilisation (e.g. gonadotrophins) are restricted to use by specialist secondary care physicians, and are categorised as RED drugs for these purposes.

 Useful Links

08.01 Cytotoxic drugs
08.01.01 Alkylating drugs
08.01.02 Anthracyclines and other cytotoxic antibiotics
08.01.03 Antimetabolites
08.01.04 Vinca alkaloids and etoposide
08.01.05 Other antineoplastic drugs
08.02 Drugs affecting the immune response
08.02.01 Antiproliferative immunosuppressants
08.02.02 Corticosteroids and other immunosuppressants
08.02.03 Anti-lymphocyte monoclonal antibodies
08.02.04 Other immunomodulating drugs
Interferon Alfa
Interferon beta
Interferon gamma
BCG bladder instillation
Dimethyl fumarate
Glatiramer acetate
Lenalidomide, pomalidomide, and thalidomide
08.03 Sex hormones and hormone antagonists in malignant disease
08.03.01 Oestrogens
08.03.02 Progestogens
08.03.03 Androgens
08.03.04 Hormone antagonists Breast cancer Prostate cancer and gonadorelin analogues
Gonadorelin analogues
Gonadotrophin-releasing hormone antagonists Somatostatin analogues